Actinic Keratosis Treatment Market Size Hits US$ 10.12 billion by 2030

SHARE THIS ARTICLE

The global actinic keratosis treatment market size is expected to be worth around US$ 10.12 billion by 2030, according to a new report by Vision Research Reports.

The global actinic keratosis treatment market size was valued at US$ 7.8 billion in 2020 and is anticipated to grow at a CAGR of 7.3% during forecast period 2021 to 2030.

Get Sample Copy of This Report (Including TOC, List of Tables & Figures, and Chart)@ https://www.visionresearchreports.com/report/sample/38605

Actinic Keratosis Treatment Market (By Therapy: Topical, Surgery, Photodynamic Therapy; By Drug Class: Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers, Others; By End-use: Hospitals, Private Clinics, Homecare, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

Report Coverage

Report Scope Details
Market Size USD 10.12 billion by 2030
Growth Rate CAGR of 7.3% From 2021 to 2030
Base Year 2021
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Therapy, Drug class, End-use
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Almirall, S.A.; Biofrontera AG; Bausch Health Companies, Inc.; LEO Pharma A/S; Sun Pharmaceutical Industries Ltd.; Novartis AG; GALDERMA; Hill Dermaceuticals, Inc.

Growth Factors

 The increasing prevalence of the disease coupled with an increasing geriatric population and rising awareness about the disease are factors expected to drive the growth over the forecast period. For instance, in the U.S. and Europe, the prevalence of the disease ranges from 11 to 26%, due to which it is the most commonly treated dermatologic disease in the outpatient setting in the U.S. Moreover, the prevalence is highest in Australia with an estimation of 37 to 55% in adults aged 40 years and above. However, the outbreak of COVID-19 has affected the market adversely.

Report Highlights

The surgical therapy segment dominated the global market in 2020 with a revenue share of more than 67%. The segment is anticipated to maintain its dominance over the forecast period. The high penetration of cryotherapy for the treatment of AK will drive the segment growth. This is also called field therapy and has a low associated risk of scarring. The photodynamic therapy segment is anticipated to grow at a CAGR of 7.10% over the forecast period.

The nucleoside metabolic inhibitors drug class segment led the global market in 2020 with a revenue share of over 32%. The growth was driven by the strong commercial performances of Carac, Efudex, and Fluoroplex. Moreover, increasing awareness about diagnostics and treatment strategies for this disease has driven the widespread adoption of field-directed treatments, such as 5-fluorouracil.

The photo-enhancers segment is estimated to witness the fastest CAGR during the forecast period. Photodynamic therapy is gaining ground and is expected to positively impact the market growth of photo-enhancers.

The photo-enhancers segment is estimated to witness the fastest CAGR during the forecast period. Photodynamic therapy is gaining ground and is expected to positively impact the market growth of photo-enhancers.

The home care segment is anticipated to grow at the fastest CAGR over the forecast period. Increasing adoption of topical therapies, availability of OTC drugs, and patient convenience are factors driving the segment growth over the forecast period.

North America accounted for the highest revenue share of more than 42% of the global market in 2020. It is anticipated to maintain its dominance over the forecast period.

Asia Pacific is estimated to grow at the fastest CAGR over the forecast period due to an increase in the treatment rate of the disease, rising consumer disposable income, and high disease prevalence in certain countries, such as Australia and New Zealand.

Key Players

  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • GALDERMA
  • Hill Dermaceuticals, Inc.
  • Viatris Inc.
  • Mylan N.V.
  • Bausch Health Companies, Inc.
  • LEO Pharma A/S
  • Almirall, S.A.
  • Biofrontera AG
  • 3M

Market Segmentation

  • Therapy
    • Topical
    • Surgery
    • Photodynamic Therapy
  • Drug Class
    • Nucleoside Metabolic Inhibitor
    • NSAIDs
    • Immune Response Modifiers
    • Photoenhancers
    • Others
  • End-use
    • Hospitals
    • Private Clinics
    • Homecare
    • Others
  • Regional
    • North America
      • U.S
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia
      • South Korea
    • Latin America
      • Argentina
      • Brazil
      • Mexico
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa

Buy This Premium Research Report, click here@ https://www.visionresearchreports.com/report/cart/38605 or call: +1 9197 992 333

Daksh

Daksh is an SEO Analyst having 3 years of experienced. we can quickly understand and support initiatives that will contribute to the goals and success of client campaigns. and also Perform keyword research in coordination with client business objectives to optimize existing content and uncover new opportunities.

View all posts by Daksh →

Leave a Reply

Your email address will not be published.